Top-line results indicate oral GLP-1 well-tolerated, tied to weight loss in phase 1 trial
September 09, 2024 2 min read Add topic to email alerts Receive an email when...
Phase
LUM-201 phase 2 data for PGHD with Andrew Dauber, MD, MMSc
In this Contemporary Pediatrics interview, Andrew Dauber, MD, MSSc, Chief of Endocrinology at Children’s National Hospital in Washington, DC, broke...
Rivus Pharmaceuticals’ Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure
– Data from the HuMAIN study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) will be presented...
